Currently, there are 1.12B common shares owned by the public and among those 1.12B shares have been available to trade.
Insiders at the company have transacted a total of 2 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 2 occasions, with total insider shares sold totaling 77,421 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
However, the script later moved the day high at 13.09, down -1.23%. The company’s stock has a 5-day price change of -2.35% and 39.05% over the past three months. TEVA shares are trading 23.47% year to date (YTD), with the 12-month market performance up to 29.42% higher. It has a 12-month low price of $7.09 and touched a high of $13.35 over the same period. TEVA has an average intraday trading volume of 10.40 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 3.39%, 12.37%, and 35.91% respectively.
Institutional ownership of Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) shares accounts for 52.45% of the company’s 1.12B shares outstanding.
It has a market capitalization of $14.45B and a beta (3y monthly) value of 1.04. The earnings-per-share (ttm) stands at -$0.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.58% over the week and 2.86% over the month.
Analysts forecast that Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will achieve an EPS of $0.52 for the current quarter, $0.58 for the next quarter and $2.64 for 2025. The lowest estimate earnings-per-share for the quarter is $0.47 while analysts give the company a high EPS estimate of $0.57. Comparatively, EPS for the current quarter was $0.4 a year ago. Earnings per share for the fiscal year are expected to decrease by -6.28%, and 10.03% over the next financial year. EPS should shrink at an annualized rate of 1.60% over the next five years, compared to 26.63% over the past 5-year period.
Looking at the support for the TEVA, a number of firms have released research notes about the stock. Piper Sandler stated their Overweight rating for the stock in a research note on February 12, 2024, with the firm’s price target at $12-$19. Jefferies coverage for the Teva- Pharmaceutical Industries Ltd. ADR (TEVA) stock in a research note released on January 23, 2024 offered a Buy rating with a price target of $14. Piper Sandler was of a view on January 03, 2024 that the stock is Neutral, while HSBC Securities gave the stock Buy rating on December 18, 2023, issuing a price target of $13. UBS on their part issued Buy rating on November 27, 2023.
